Clik here to view.
Clik here to view.
Bioventus认可EXOGEN长达25年经过验证的骨愈合功效
北卡罗莱纳州达勒姆 (美国商业资讯)–骨科解决方案的全球领导者Bioventus认可其EXOGEN超声骨愈合系统长达25年经过验证的骨愈合功效。EXOGEN使用低强度脉冲超声波(LIPUS)来帮助刺激机体的自然骨愈合机制并促进骨折愈合。对于无法自行愈合的骨折，其愈合率达86% 1，对于有适应证的新发骨折，愈合速度提高38% 2, 3。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and...
DUBLIN & CAMBRIDGE, United Kingdom & BRISBANE, Australia Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation,...
View ArticleClik here to view.
TransEnterix Announces St. Marianna University School of Medicine Toyoko...
RESEARCH TRIANGLE PARK, N.C. TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive...
View ArticleClik here to view.
First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL®...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
患者安全运动基金会任命新董事长；宣布目标是在2030年之前实现可预防的患者死亡为零
加州尔湾 (美国商业资讯)–患者安全运动基金会(Patient Safety Movement Foundation, PSMF)是一家全球性非营利组织，致力于联合医疗保健生态系统的参与者，识别导致患者死亡的挑战，并创建可减少此类死亡的可付诸行动的解决方案。该基金会欣然宣布任命新董事长Michael A.E. Ramsay, MD,...
View ArticleClik here to view.
Clik here to view.
NTHU’s Boron Neutron Capture Therapy Center Begins Treating Overseas Brain...
HSINCHU, Taiwan On February 14th the melodious strains of the fourth movement of Mahler’s Fifth Symphony were heard inside the building of Tsing Hua Open pool Reactor (THOR) at National Tsing Hua...
View ArticleClik here to view.
Aroa Biosurgery Opens New Pathway for Advanced Wound Treatment Amidst...
SAN DIEGO Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are battling to treat wounds amid disruption to many existing U.S. facilities for...
View ArticleClik here to view.
AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and...
View ArticleAVITA Medical Announces Intention to Redomicile to the United States of America
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (Company) (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical...
View ArticleAVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
Neuraptive Therapeutics宣布FDA核准周围神经损伤患者治疗新药NTX-001的IND申请
费城 (美国商业资讯)–Neuraptive Therapeutics, Inc. (Neuraptive)是一家临床阶段生物技术公司，致力于开发新药和医疗产品以解决周围神经损伤(PNI)治疗中未获满足的需求。该公司今天宣布，美国食品药品管理局(FDA)已核准Neuraptive在研新药(IND) NTX-001用于急性单支横断性PNI患者的申请。 执行副总裁兼研发部主管Evan...
View ArticleClik here to view.
ニューラプティブ・セラピューティクス、末梢神経損傷患者を治療するための新規手法となるNTX-001のIND申請をFDAが承認と発表
フィラデルフィア （ビジネスワイヤ） — 末梢神経損傷（PNI）の治療における未充足ニーズに対処するための新規の治療薬と医療用製品の開発に専心する臨床段階のバイオテクノロジー企業であるニューラプティブ・セラピューティクス（以下、「ニューラプティブ」）は本日、急性単神経切断PNI患者でのNTX-001に対する当社の新薬臨床試験開始届（IND）を米国食品医薬品局（FDA）が承認したと発表しました。...
View ArticleClik here to view.
Study Finds Noninvasive, Continuous Masimo PVi® Monitoring More Valuable Than...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) announced today the findings of a study published in the Journal of Anesthesiology and Reanimation Specialists’ Society in which researchers compared two...
View ArticleClik here to view.
手術中における輸液管理の指針として非侵襲的・連続的Masimo PVi®モニタリングが中心静脈圧測定よりも有益であることを示す研究
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、Journal of Anesthesiology and Reanimation Specialists’ Society誌に掲載された研究結果を発表しました。研究では、研究者らが、Masimo...
View ArticleClik here to view.
研究发现，无创连续Masimo PVi®监测对指导术中体液处治的价值优于中央静脉压测量
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天宣布了《麻醉与复苏专家学会杂志》发表的一项研究结果，该研究的研究人员比较脊柱骨科手术中两种体液处治方法，包括Masimo PVi®。与有创间歇性中心静脉压(CVP)测量相比，无创连续脉搏灌注变异指数(PVi)监测时“心脏更稳定、补液更少、血管容积状况的评估结果更精准。”1 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
AVITA Medical Limited Proposed redomiciliation to the United States of...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (Company) (ASX:AVH, NASDAQ:RCEL) is pleased to announce that the Federal Court of Australia (Court) has today approved orders to...
View ArticleClik here to view.
AVITA Medical to Participate at Oppenheimer’s MedTech Summit
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (Company) (ASX:AVH) (NASDAQ:RCEL) today announced that management will participate virtually in the 1-on-1 meetings at the upcoming...
View Article